Candidiasis Market Size & Trends 2020 – expected to reach US$ 1,307.2 Million With CAGR of 4.6% by 2026, Owing Increasing Prevalence of Candidiasis
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Candidiasis Market, by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 873.8 million in 2017, and is projected to exhibit a CAGR of 4.6% over the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/229
Increasing prevalence of candidiasis is expected to fuel growth of the global candidiasis market over the forecast period. For instance, according to the study, ‘National Burden of Candidemia, United States, 2017, published in November 2018, in the journal Open Forum Infectious Diseases, invasive candidiasis (candidemia) is one of the most common bloodstream infections in the U.S. and the average incidence for the disease was around 9 per 100,000 people during 2013–2017.
R&D of new vaccines for the treatment of candidiasis is expected to boost growth of the global candidiasis market over the forecast period. For instance, in August 2019, researchers from the Los Angeles Biomedical Research Institute (LA BioMed), a spinoff company of NovaDigm Therapeutics, started developing the vaccine-NDV-3A to prevent infections caused by C. auris in humans, after successfully immunizing and demonstrating its clinical efficacy in mice.
Quick Buy – Candidiasis Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/229
Increasing number of clinical trials related to the treatment of fungal diseases is expected to propel growth of the global candidiasis market. For instance, in 2017, the University Hospital of Cologne initiated a clinical trial to evaluate drug candidate SCY-078 in patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment, in Europe.
Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2018, Viamet Pharmaceuticals (NC), Inc. acquired Viamet Pharmaceuticals. The acquisition included the company’s product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection. Similarly, in 2014, NovaDigm Therapeutics acquired the rights to three Candida vaccine antigens from the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center.
Browse 40 Market Data Tables and 38 Figures spread through 178 Pages and in-depth TOC on “Candidiasis Market”- Global Forecast to 2026 by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global candidiasis market press release, click the link below: https://www.coherentmarketinsights.com/press-release/candidiasis-market-to-surpass-us-13072-million-by-2026-2454
The global candidiasis market is expected to exhibit a CAGR of 4.6% over the forecast period
Among drug class, the azoles segment held dominant position in the global candidiasis market in 2017. Azoles are considered as the first-line agents in the treatment of various types of candidiasis such as esophageal and vaginal candidiasis.
Among type, the vaginal candidiasis segment held dominant position in the global candidiasis market in 2017, owing to R&D in this segment
Among route of administration, the oral segment held dominant position in the global candidiasis market in 2017. Several antifungal drugs used for the treatment and management of candidiasis are available in oral dosage form.
Major players operating in the global candidiasis market include Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
Got any Query? Feel free to ask us at https://www.coherentmarketinsights.com/insight/talk-to-analyst/229About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire